• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Joenja

How Pharming’s Joenja resubmission could reopen the FDA pathway for pediatric APDS treatment

By Soujanya Ravi on June 4, 2026   Pharma & Biotech  

How Pharming’s Joenja resubmission could reopen the FDA pathway for pediatric APDS treatment

Find out how Pharming’s Joenja sNDA resubmission could reopen the FDA pathway for younger children with APDS.

Recent Posts

  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
  • Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
  • Why Multi Radiance Medical’s MR5 ACTIV PRO clearance matters for tendon pain treatment
  • Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate
  • Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset
  • Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight
  • Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes